Advertisement
YOU ARE HERE: LAT HomeCollectionsLicenses

CALIFORNIA: News and Insights on Business in the Golden
State | HEALTH | THE STATE

Cell Genesys Licenses Antibody Technology

January 01, 1998| Bloomberg News

Cell Genesys Inc.'s Abgenix unit said it has licensed technology for using mice to develop human antibodies to Pfizer Inc., an agreement that could bring it $30 million plus eventual royalties. The worldwide research collaboration and licensing agreement will give Pfizer access to Abgenix's XenoMouse, a breed of mice that can produce human antibodies to fight diseases when given human genes, Abgenix said in a statement. Pfizer will use the mice to develop antibodies to fight three specific viruses or bacteria that cause disease; the companies declined to name them. Pfizer will handle the product development, manufacturing and marketing of any drugs produced from the collaboration. Fremont-based Cell Genesys shares rose 50 cents to close at $8.50 on Nasdaq. Shares of New York-based Pfizer fell $1 to close at $74.56 on the NYSE.

Advertisement
Los Angeles Times Articles
|
|
|